For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Imbria Pharmaceuticals, Inc.

USPTO Granted Patents = 23

EPO Patents = 3

Trademarks = 2

Forward Citations = 71

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

Andrew D Levin (9 out of 24 patents)

Paul Chamberlin (8 out of 8 patents)

Jaikrishna Patel (8 out of 8 patents)

4. Neil Buckley (6 out of 6 patents)

5. Dan Belmont (6 out of 6 patents)

6. Sarah Bethune (4 out of 4 patents)

7. Krista Diaz (4 out of 4 patents)

8. Bryan Hauser (2 out of 2 patents)

9. Kumar Kannan (2 out of 2 patents)

10. Myoung Goo Kim (2 out of 2 patents)

11. David-Alexandre Gros (2 out of 2 patents)

12. Jai Patel (2 patents)

23 patents: Sort by Forward Citations

1. 12649720 - Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate (2026-06-09),

2. 12569480 - Methods of treating fibrosis using compounds that promote glucose oxidation (2026-03-10),

3. 12502389 - Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine (2025-12-23),

4. 12318453 - Compositions and methods for increasing efficiency of cardiac metabolism (2025-06-03),

5. 12318382 - Methods of treating rheumatic diseases using trimetazidine-based compounds (2025-06-03),

6. 12285428 - Methods of treating kidney conditions using modified forms of trimetazidine (2025-04-29),

7. 12233058 - Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine (2025-02-25),

8. 12110275 - Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl] piperazin-1-yl]ethyl pyridine-3-carboxylate (2024-10-08),

9. 12076318 - Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine (2024-09-03),

10. 12065410 - Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate (2024-08-20),

11. 11969422 - Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine (2024-04-30),

12. 11883396 - Methods of treating kidney conditions using modified forms of trimetazidine (2024-01-30),

13. 11844840 - Compositions and methods for increasing efficiency of cardiac metabolism (2023-12-19),

14. 11793807 - Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine (2023-10-24),

15. 11780811 - Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate (2023-10-10),

Company Overview

Imbria Pharmaceuticals, Inc. is a biotechnology company based in Boston, MA, focused on developing innovative therapies for patients with unmet medical needs. The company specializes in the discovery and advancement of novel drug candidates, particularly in the fields of neurology and rare diseases. Leveraging cutting-edge research and technology, Imbria aims to transform the treatment landscape through its commitment to scientific excellence and patient-centric solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

23 Patents

#103 in Boston, MA

#868 in Massachusetts

#14,428 in US

#27,685 in the World

Boston, MA, United States of America

Imbria Pharmaceuticals, Inc.

Forward Citations = 71

11 inventors:

Andrew D Levin (9 out of 24 patents)

Paul Chamberlin (8 out of 8 patents)

Jaikrishna Patel (8 out of 8 patents)

4. Neil Buckley (6 out of 6 patents)

5. Dan Belmont (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Imbria Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/imbria-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…